318 related articles for article (PubMed ID: 34645909)
1. Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker.
Poblocka M; Bassey AL; Smith VM; Falcicchio M; Manso AS; Althubiti M; Sheng X; Kyle A; Barber R; Frigerio M; Macip S
Sci Rep; 2021 Oct; 11(1):20358. PubMed ID: 34645909
[TBL] [Abstract][Full Text] [Related]
2. Galactose-modified duocarmycin prodrugs as senolytics.
Guerrero A; Guiho R; Herranz N; Uren A; Withers DJ; Martínez-Barbera JP; Tietze LF; Gil J
Aging Cell; 2020 Apr; 19(4):e13133. PubMed ID: 32175667
[TBL] [Abstract][Full Text] [Related]
3. Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells.
Le HH; Cinaroglu SS; Manalo EC; Ors A; Gomes MM; Duan Sahbaz B; Bonic K; Origel Marmolejo CA; Quentel A; Plaut JS; Kawashima TE; Ozdemir ES; Malhotra SV; Ahiska Y; Sezerman U; Bayram Akcapinar G; Saldivar JC; Timucin E; Fischer JM
EBioMedicine; 2021 Nov; 73():103646. PubMed ID: 34689087
[TBL] [Abstract][Full Text] [Related]
4. Chemical Strategies for the Detection and Elimination of Senescent Cells.
García-Fleitas J; García-Fernández A; Martí-Centelles V; Sancenón F; Bernardos A; Martínez-Máñez R
Acc Chem Res; 2024 May; 57(9):1238-1253. PubMed ID: 38604701
[TBL] [Abstract][Full Text] [Related]
5. Potential Use of Senolytics for Pharmacological Targeting of Precancerous Lesions.
Saleh T; Carpenter VJ
Mol Pharmacol; 2021 Dec; 100(6):580-587. PubMed ID: 34544896
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the HDAC/PI3K inhibitor CUDC-907 as a novel senolytic.
Al-Mansour F; Alraddadi A; He B; Saleh A; Poblocka M; Alzahrani W; Cowley S; Macip S
Aging (Albany NY); 2023 Mar; 15(7):2373-2394. PubMed ID: 36988504
[TBL] [Abstract][Full Text] [Related]
7. Bone-targeted delivery of senolytics to eliminate senescent cells increases bone formation in senile osteoporosis.
Xing X; Tang Q; Zou J; Huang H; Yang J; Gao X; Xu X; Ma S; Li M; Liang C; Tan L; Liao L; Tian W
Acta Biomater; 2023 Feb; 157():352-366. PubMed ID: 36470392
[TBL] [Abstract][Full Text] [Related]
8. Biomolecular Evaluation of Piceatannol's Effects in Counteracting the Senescence of Mesenchymal Stromal Cells: A New Candidate for Senotherapeutics?
Alessio N; Squillaro T; Lettiero I; Galano G; De Rosa R; Peluso G; Galderisi U; Di Bernardo G
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769049
[TBL] [Abstract][Full Text] [Related]
9. A guide to senolytic intervention in neurodegenerative disease.
Lee S; Wang EY; Steinberg AB; Walton CC; Chinta SJ; Andersen JK
Mech Ageing Dev; 2021 Dec; 200():111585. PubMed ID: 34627838
[TBL] [Abstract][Full Text] [Related]
10. From the divergence of senescent cell fates to mechanisms and selectivity of senolytic drugs.
L'Hôte V; Mann C; Thuret JY
Open Biol; 2022 Sep; 12(9):220171. PubMed ID: 36128715
[TBL] [Abstract][Full Text] [Related]
11. A pipeline for senolytics.
Khosla S
J Clin Invest; 2024 May; 134(9):. PubMed ID: 38690734
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the discovery of senolytics.
Zhang L; Pitcher LE; Prahalad V; Niedernhofer LJ; Robbins PD
Mech Ageing Dev; 2021 Dec; 200():111587. PubMed ID: 34656616
[TBL] [Abstract][Full Text] [Related]
13. A geroscience motivated approach to treat Alzheimer's disease: Senolytics move to clinical trials.
Gonzales MM; Krishnamurthy S; Garbarino V; Daeihagh AS; Gillispie GJ; Deep G; Craft S; Orr ME
Mech Ageing Dev; 2021 Dec; 200():111589. PubMed ID: 34687726
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Potential of Senolytics in Cardiovascular Disease.
Dookun E; Passos JF; Arthur HM; Richardson GD
Cardiovasc Drugs Ther; 2022 Feb; 36(1):187-196. PubMed ID: 32979174
[TBL] [Abstract][Full Text] [Related]
15. The Emergence of Senescent Surface Biomarkers as Senotherapeutic Targets.
Rossi M; Abdelmohsen K
Cells; 2021 Jul; 10(7):. PubMed ID: 34359910
[TBL] [Abstract][Full Text] [Related]
16. Senolytics and the compression of late-life mortality.
Kowald A; Kirkwood TBL
Exp Gerontol; 2021 Nov; 155():111588. PubMed ID: 34637949
[TBL] [Abstract][Full Text] [Related]
17. The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice.
Xu Q; Fu Q; Li Z; Liu H; Wang Y; Lin X; He R; Zhang X; Ju Z; Campisi J; Kirkland JL; Sun Y
Nat Metab; 2021 Dec; 3(12):1706-1726. PubMed ID: 34873338
[TBL] [Abstract][Full Text] [Related]
18. New Senolysis Approach via Antibody-Drug Conjugate Targeting of the Senescent Cell Marker Apolipoprotein D for Skin Rejuvenation.
Takaya K; Asou T; Kishi K
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982931
[TBL] [Abstract][Full Text] [Related]
19. Senolytics and senomorphics: Natural and synthetic therapeutics in the treatment of aging and chronic diseases.
Lagoumtzi SM; Chondrogianni N
Free Radic Biol Med; 2021 Aug; 171():169-190. PubMed ID: 33989756
[TBL] [Abstract][Full Text] [Related]
20. Promises and challenges of senolytics in skin regeneration, pathology and ageing.
Pils V; Ring N; Valdivieso K; Lämmermann I; Gruber F; Schosserer M; Grillari J; Ogrodnik M
Mech Ageing Dev; 2021 Dec; 200():111588. PubMed ID: 34678388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
